SEC Company Response from IMMUNOMEDICS INC (CIK 0000722830) — Oct 2, 2020
IMMUNOMEDICS INC (CIK 0000722830)
Date: Oct. 2, 2020 · CIK: 0000722830 · Accession: 0001104659-20-111786
AI Filing Summary & Sentiment
Letter
VIA EDGAR SUBMISSION Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3561 Schedule 14D-9 filed on September 24, 2020 File No. 005-35857
Re: Immunomedics, Inc.
Dear Mr. Afshar:
On behalf of our client, Immunomedics, Inc. (“Immunomedics” or the “Company”), set forth below are the responses of the Company to the comments of the Staff (the “Staff”) in the Office of Mergers and Acquisitions of the Division of Corporation Finance of the U.S. Securities and Exchange Commission set forth in your letter, dated September 30, 2020 (the “Comment Letter”), regarding the above-referenced Schedule 14D-9 (the “Schedule 14D-9”). In connection with this letter, the Company is filing Amendment No. 2 to the Schedule 14D-9.
October 2, 2020
Page 2
For your convenience, the numbered paragraphs of this letter correspond to the numbered paragraphs of the Comment Letter. To assist your review, we have included the text of the Staff’s comments in bold below.
****
Schedule 14D-9
Item 3. Past Contacts, Transactions, Negotiations and Agreements, page 2.
1. We note that in the beneficial ownership table under the header “Outstanding Shares Held by Executive Officers and Directors,” there is a notation “(1)” next to the column titled “Number of Shares.” Please revise to clarify the footnote to which that notation relates.
In response to the Staff’s comment, Immunomedics has revised its disclosure in Amendment No. 2 to the Schedule 14D-9.
Item 4. The Solicitation or Recommendation, page 12.
2. In your response letter, please confirm whether the terms the “Forecasts,” the “management forecasts” and the “Immunomedics Forecasts”—as defined in the summaries of Centerview’s and BofA Securities’ opinions in this section and in their opinions in Annexes A and B—are referring to the Projections disclosed in this section.
In response to the Staff’s comment, Immunomedics confirms that the terms the “Forecasts,” the “management forecasts” and the “Immunomedics Forecasts” refer to the Projections disclosed in this section.
****
October 2, 2020
Page 3
If you have any questions regarding the foregoing, please contact the undersigned at (212) 403-1005.
Very truly yours,
/s/ Victor Goldfeld
Show Raw Text
CORRESP
1
filename1.htm
October 2, 2020
VIA EDGAR SUBMISSION
Mr. Valian A. Afshar
Office of Mergers and Acquisitions
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-3561
Re: Immunomedics, Inc.
Schedule 14D-9 filed on September 24, 2020
File No. 005-35857
Dear Mr. Afshar:
On behalf of our client, Immunomedics, Inc.
(“Immunomedics” or the “Company”), set forth below are the responses of the Company to the comments of
the Staff (the “Staff”) in the Office of Mergers and Acquisitions of the Division of Corporation Finance of the U.S.
Securities and Exchange Commission set forth in your letter, dated September 30, 2020 (the “Comment Letter”),
regarding the above-referenced Schedule 14D-9 (the “Schedule 14D-9”). In connection with this letter, the Company is
filing Amendment No. 2 to the Schedule 14D-9.
October 2, 2020
Page 2
For your convenience, the numbered paragraphs
of this letter correspond to the numbered paragraphs of the Comment Letter. To assist your review, we have included the text of
the Staff’s comments in bold below.
****
Schedule 14D-9
Item 3. Past Contacts, Transactions, Negotiations and
Agreements, page 2.
1. We note that in the beneficial ownership table under the header “Outstanding Shares Held by Executive Officers and
Directors,” there is a notation “(1)” next to the column titled “Number of Shares.” Please revise
to clarify the footnote to which that notation relates.
In response to the Staff’s comment, Immunomedics has revised its disclosure in
Amendment No. 2 to the Schedule 14D-9.
Item 4. The Solicitation or Recommendation, page 12.
2. In your response letter, please confirm whether the terms the “Forecasts,” the “management forecasts”
and the “Immunomedics Forecasts”—as defined in the summaries of Centerview’s and BofA Securities’
opinions in this section and in their opinions in Annexes A and B—are referring to the Projections disclosed in this section.
In response to the Staff’s comment, Immunomedics confirms that the terms the
“Forecasts,” the “management forecasts” and the “Immunomedics Forecasts” refer to the
Projections disclosed in this section.
****
October 2, 2020
Page 3
If you have any questions regarding the foregoing, please contact the undersigned at (212)
403-1005.
Very truly yours,
/s/ Victor Goldfeld
Victor Goldfeld
Cc: Usama Malik, Chief Financial Officer, Chief Business
Officer, Immunomedics, Inc.
Jared Freedberg, General Counsel, Corporate Secretary, Immunomedics, Inc.